Peter Taylor

Publications (2)12.42 Total impact

• Article: Reevaluation of the role of duration of morning stiffness in the assessment of rheumatoid arthritis activity.

  Nasim A Khan, Yusuf Yazici, Jaime Calvo-Alen, Jolanta Dadoniene, Laure Gossec, Troels M Hansen, Margriet Huisman, Riina Kallikorm, Raili Muller, Margareth Liveborn, Rolf Oding, Elena Luchikhina, Antonio Naranjo, Sylejman Rexhepi, Peter Taylor, Witold Tlustochowich, Afrodite Tsirogianni, Tuulikki Sokka
  [show abstract] [hide abstract]
  ABSTRACT: To evaluate the utility of the duration of morning stiffness (MS), as a patient-reported outcome (PRO), in assessing rheumatoid arthritis (RA) disease activity. We acquired information on 5439 patients in QUEST-RA, an international database of patients with RA evaluated by a standard protocol. MS duration was assessed from time of waking to time of maximal improvement. Ability of MS duration to differentiate RA activity states, based on Disease Activity Score (DAS)28, was assessed by analysis of variance; and a receiver-operating characteristic (ROC) curve was plotted for discriminating clinically active (DAS28 > 3.2) from less active (DAS28 <or= 3.2) RA. Mixed-effect analysis of covariance (ANCOVA) models were used to assess the utility of adding MS duration to Routine Assessment of Patient Index Data (RAPID)3, a PRO index based on physical function, pain, and general health (GH), in predicting the 3-variable DAS28 (DAS28v3). MS duration had moderate correlation (r = 0.41-0.48) with pain, Health Assessment Questionnaire, and GH; and weak correlation (r = 0.23-0.39) with joint counts and erythrocyte sedimentation rate. MS duration differed significantly among patients with different RA activity (p < 0.001). The area under the ROC curve of 0.74 (95% CI 0.72-0.75) showed moderate ability of MS duration to differentiate clinically active from less active RA. ANCOVA showed significant interactive effects between RAPID3 and the MS duration categories (p = 0.0005) in predicting DAS28v3. The effect of MS was found to be clinically important in patients with the low RAPID3 scores (< 6) in whom the presence of MS may indicate clinically active disease (DAS28v3 > 3.2). MS duration has a moderate correlation with RA disease activity. Assessment of MS duration may be clinically helpful in patients with low RAPID3 scores.
  The Journal of Rheumatology 11/2009; 36(11):2435-42. · 3.69 Impact Factor
• Article: QUEST-RA: quantitative clinical assessment of patients with rheumatoid arthritis seen in standard rheumatology care in 15 countries.

  Tuulikki Sokka, Hannu Kautiainen, Sergio Toloza, Heidi Mäkinen, Suzan M M Verstappen, Merete Lund Hetland, Antonio Naranjo, Eva Baecklund, Gertraud Herborn, Rolf Rau, Massimiliano Cazzato, Laure Gossec, Vlado Skakic, Feride Gogus, Stanislaw Sierakowski, Barry Bresnihan, Peter Taylor, Catherine McClinton, Theodore Pincus
  [show abstract] [hide abstract]
  ABSTRACT: To conduct a cross-sectional review of non-selected consecutive outpatients with rheumatoid arthritis (RA) as part of standard clinical care in 15 countries for an overview of the characteristics of patients with RA. The review included current disease activity using data from clinical assessment and a patient self-report questionnaire, which was translated into each language. Data on demographic, disease and treatment-related variables were collected and analysed using descriptive statistics. Variation in disease activity on DAS28 (disease activity score on 28-joint count) within and between countries was graphically analysed. A median regression model was applied to analyse differences in disease activity between countries. Between January 2005 and October 2006, the QUEST-RA (Quantitative Patient Questionnaires in Standard Monitoring of Patients with Rheumatoid Arthritis) project included 4363 patients from 48 sites in 15 countries; 78% were female, >90% Caucasian, mean age was 57 years and mean disease duration was 11.5 years. More than 80% of patients had been treated with methotrexate in all but three countries. Overall, patients had an active disease with a median DAS28 of 4.0, with a significant variation between countries (p<0.001). Among 42 sites with >50 patients included, low disease activity of DAS28 <or=3.2 was found in the majority of patients in seven sites in five countries; in eight sites in five other countries, >50% of patients had high disease activity of DAS28 >5.1. This international multicentre cross-sectional database provides an overview of clinical status and treatments of patients with RA in standard clinical care in 2005-6 including countries that are infrequently involved in clinical research projects.
  Annals of the Rheumatic Diseases 11/2007; 66(11):1491-6. · 8.73 Impact Factor